Albany, NY -- (SBWIRE) -- 11/06/2018 -- DelveInsight has announced the addition of the "Pruritis -Market Insights, Epidemiology and Market Forecast- 2027" drug pipelines to their offering.

The report provides an overview of the disease and market size of Pruritis for the seven major markets i.e., United States, EU5 (France, Germany, Italy, Spain, UK) and Japan. The Report covers the overview, treatment practice and forecasted epidemiology of Pruritis from 2018 to 2027 segmented by seven major markets.

Request for sample pages

Pruritus, or itching, although considered a benign symptom, is a frequent complaint heard by dermatologists and primary care physicians. It can have adverse effects on a patient's wellbeing and can be incapacitating when severe. The mechanisms of pruritus are not particularly well understood and are compounded by the subjective nature of the process itself. The condition occurs with a host of dermatological conditions, but can also be a marker of systemic disease. Physiologically, itching is the conscious expression of cutaneous sensations that evoke the well-known scratch reflex. The purpose of this reflex is the removal of the noxious stimulus. Unfortunately, scratching can cause further damage to the skin and can perpetuate the problem. Severe pruritus can be relieved by self-trauma, essentially replacing itching with pain, but such action can result in chronic skin changes, such as lichenification, erythema, excoriation, and even lacerations. Pruritus may be acute or chronic, localized or generalized.

Topical treatments of pruritus include Moisturizers, emollients and barrier repair creams, Topical corticosteroids, Topical calcineurin inhibitors (such as tacrolimus and pimecrolimus), Topical Antihistamines (Doxepin), topical antipruritic (Menthol), Capsaicin, Salicylic acid, Local anesthetics (pramoxine 1 percent, lidocaine, eutectic mixture of lidocaine and prilocaine) and Cannabinoids.

On the other hand, treatment with oral medication may be necessary to relieve the itch in severe cases of pruritus. Some of the drug classes which are prescribed to patients with severe conditions include antihistamines, tricyclic antidepressants, tetracyclic antidepressants, anti-epileptic drugs, and opioid antagonists. Combination therapy is preferred in order to manage chronic severe itch, which is otherwise difficult to treat.

Geography Covered

1. The United States
2. EU5 (Germany, France, Italy, Spain and the United Kingdom)
3. Japan

Study Period: 2016-2027
Drug Companies

1. Cara Therapeutics,
2. Menlo Therapeutics
3. Sienna Biopharmaceuticals
4. Sanwa Kagaku Kenkyusho
And many others

Drugs covered

1. Serlopitant
2. CR845
3. SNA-120
And many others

Report Scope

The report covers the descriptive overview of Pruritis explaining its pathophysiology, disease classification, diagnostic approaches and treatment algorithm. The report provides insight into the epidemiology of the disease and its treatment in the 7 MM covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan. The report is a comprehensive account of both the current and emerging therapies covering the impact of the new therapies on the current treatment landscape. The report also reviews the detailed historical and forecasted Pruritis market size covering the drug outreach in 7MM. The report provides an understanding of the future competition in Pruritis by reviewing the market drivers and barriers.